AM-Pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our proprietary compound, ilofotase alfa, is being developed as a potential enzyme replacement therapy for adult hypophosphatasia (HPP) patients. In a Phase 1b clinical proof of concept study in adult HPP patients, ilofotase alfa showed a pronounced effect on all HPP disease-specific biomarkers and normalized alkaline phosphatase activity levels. There were no safety concerns with ilofotase alfa in this study, consistent with previous clinical studies with ilofotase alfa in other indications involving about 1000 patients. These data support its further development as a treatment option for adult HPP patients who are currently underserved. We are a dedicated team driven to bring treatment options to patients in need, their families and healthcare professionals.